Multi-pharmaceutical companies issued an announcement: anti-tumor drugs were approved for clinical trials

 In China, the drugs used for cancer treatment mainly include chemotherapy drugs, targeted drugs and tumor immunotherapy drugs
.
In recent years, thanks to policies such as encouraging drug R&D innovation, zero-tariff import of anti-cancer drugs, and strengthening the negotiation of medical insurance for major diseases, the sales of China's anti-tumor drug market have grown rapidly
.
At present, driven by clinical demand, anti-tumor drugs are ushering in a new era of targeted therapy and immunotherapy
.
Recently, a multi-pharmaceutical company issued an announcement saying that anti-tumor drugs have made new progress
.
As announced by Sino Biopharmaceuticals, the Group's self-developed anti-tumor Class I new drug "TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors
.
The data show that TQB2930 is a bispecific antibody targeting solid tumor cells, achieving a synergistic effect on the two targets
.
It blocks gene signals that drive tumor growth and kills tumor cells through a variety of mechanisms
.
Preclinical efficacy trials have shown that the molecule can significantly inhibit tumor growth
.
CSPC announced that the anti-tumor nano-drug "Cisplatin Micellar Injection" developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.
, Ltd.
, a subsidiary of the company, has been approved by the State Drug Administration of China and can be used for clinical trials in China test
.
Cisplatin Micellar Injection belongs to Category 2 of the Chinese chemical registration classification, and there is no similar product in the world at present
.
The clinical indications approved this time are advanced malignant solid tumors.
Based on the results of preclinical studies, the product is expected to show good results in clinical trials
.
Data show that cisplatin is the first-line drug for the treatment of various solid tumors, but serious adverse reactions such as nephrotoxicity and neurotoxicity limit its clinical application
.
The group independently developed this product using polymer block copolymers as a carrier, and achieved a number of unique advantages, including: efficient loading of cisplatin; reducing the accumulation of free drugs in normal tissues and reducing toxic and side effects; and nano-scale cisplatin Micelles can selectively target tumor regions, which is beneficial to improve the therapeutic index
.
CSPC stated that it will make every effort to promote the clinical trial of the product and strive to market the product as soon as possible
.
Under the encouragement of innovative drug policies and centralized procurement policies, the clinical research and development of innovative drugs in China is advancing rapidly
.
Among them, the field of anti-tumor drugs, as a hot disease field, has continuously made new progress
.
According to the statistics of drug types, anti-tumor drugs are still the most popular disease areas for research and development.
In March, a total of 87 drugs under development were anti-tumor drugs, accounting for 60%
.
For example, in March, Heyu Medicine has a total of two new anti-cancer drugs approved for clinical trials
.
Among them, ASK061 capsule is a selective FGFR2/3 small molecule inhibitor approved for clinical trials by the U.
S.
Food and Drug Administration and the State Food and Drug Administration of China.
As a second-generation FGFR inhibitor, ASK061 capsule is expected to achieve better clinical results.
Safety window and efficacy
.
Another drug under development, ABSK043 capsules, is a small molecule PD-L1 inhibitor
.
In multiple preclinical models, ABSK043 capsules have demonstrated anti-tumor efficacy comparable to that of an approved anti-PD-L1 antibody, and the drug is currently undergoing Phase 1 clinical trials against solid tumors in Australia
.
In terms of clinical approval of anti-tumor drugs, companies have recently released new developments.
The author has learned that in terms of anti-tumor drug R&D financing, some companies have also released new developments recently.
Financing to advance anti-tumor drug research and development
.
This is another financing after the completion of the B round of financing of 600 million yuan in early 2021
.
It is understood that Binhui Bio is an enterprise in the field of tumor immunotherapy oncolytic virus subdivision.
A candidate drug BS001 (OH2) injection developed by it has successively obtained the approval of the State Food and Drug Administration of China and the FDA of the United States.
of clinical trials
.
OH2 injection is an oncolytic virus candidate drug that selects herpes simplex virus type II (HSV2) as the carrier and has entered clinical trials.
Novel oncolytic virus drug candidates
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.